Evidence map›Paper›PMID 39516435›Full record

Observational studyDigestive diseases and sciences2024

Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.

Joëlle St-Pierre, Jeremy Klein, Natalie K Choi, Evan Fear, Silvana Pannain, David T Rubin

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Digestive diseases and sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Obesity: An Overlooked Factor in Inflammatory Bowel Disease.International journal of molecular sciences · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joëlle St-PierreInflammatory Bowel Disease Center, University of Chicago Medicine, 5841 S Maryland Ave, MC 4076, Chicago, IL, USA.
Jeremy KleinInflammatory Bowel Disease Center, University of Chicago Medicine, 5841 S Maryland Ave, MC 4076, Chicago, IL, USA.
Natalie K ChoiInflammatory Bowel Disease Center, University of Chicago Medicine, 5841 S Maryland Ave, MC 4076, Chicago, IL, USA.
Evan FearInflammatory Bowel Disease Center, University of Chicago Medicine, 5841 S Maryland Ave, MC 4076, Chicago, IL, USA.
Silvana PannainSection of Endocrinology, Diabetes and Metabolism, University of Chicago Medicine, Chicago, IL, USA.
David T RubinInflammatory Bowel Disease Center, University of Chicago Medicine, 5841 S Maryland Ave, MC 4076, Chicago, IL, USA. drubin@bsd.uchicago.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObesity in patients with IBD is increasing, accompanied by an increase in metabolic comorbidities. Although GLP-1 agonists have shown promise in weight reduction, their efficacy and safety in patients with IBD are underexplored. This study evaluated the impact of GLP-1-based therapies on weight loss and metabolic parameters in non-diabetic patients with IBD.

methodsWe conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024. The primary outcomes were changes in BMI and total body weight. Secondary outcomes included tolerability, safety, and changes in metabolic risk factors.

resultsThe study included 36 patients with IBD, predominantly female (64%), with a median age of 45.5 years (IQR 41-51.5 years). The majority (67%) had Crohn's disease (CD) and on advanced therapy (86%). BMI significantly decreased from 34.0 (IQR 31.0-38.2) to 31.0 (IQR 29.0-36.1) with GLP-1-based therapy (p < 0.0001). Total body weight (TBW) significantly decreased by a median of 8.15 kg (IQR 15.9-2.2 kg; p < 0.0001). Although a decrease in total cholesterol and glycated hemoglobin was seen, this was not statistically significant (p = 0.0634 for total cholesterol, p = 0.0536 for glycated hemoglobin). No significant changes were observed in ALT or CRP levels. The most common side effects were nausea (31%) and constipation (25%).

conclusionsSemaglutide and tirzepatide can effectively reduce BMI in non-diabetic patients with IBD with manageable side effects. However, further studies are required to explore the long-term safety of GLP-1 agonists in the IBD population.

Indexed as

Inflammatory Bowel DiseasesWeight LossAdultBody Mass IndexCohort StudiesCrohn DiseaseFemaleGlucagon-Like Peptide 1Glucagon-Like PeptidesHumansMaleMiddle AgedObesitySemaglutideTreatment OutcomeGlucagon-Like Peptide 1Glucagon-Like PeptidesSemaglutideCrohn's diseaseElevated BMIGLP-1Inflammatory bowel diseaseObesitySemaglutideTirzepatideUlcerative colitisWeight loss

Identifiers

PMID39516435

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.